These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16379885)

  • 21. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study.
    Redón J; Cea-Calvo L; Lozano JV; Fernández-Pérez C; Navarro J; Bonet A; González-Esteban J;
    J Hypertens; 2006 Apr; 24(4):663-9. PubMed ID: 16531794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial.
    Ogihara T; Saruta T; Rakugi H; Fujimoto A; Ueshima K; Yasuno S; Oba K; Takeda K; Higaki J; Nakao K;
    Hypertens Res; 2009 Apr; 32(4):248-54. PubMed ID: 19347033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy.
    Verdecchia P; Angeli F; Cavallini C; Mazzotta G; Repaci S; Pede S; Borgioni C; Gentile G; Reboldi G
    J Hypertens; 2009 Aug; 27(8):1697-704. PubMed ID: 19424088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study.
    Foley RN; Collins AJ; Herzog CA; Ishani A; Kalra PA
    Kidney Blood Press Res; 2009; 32(1):37-44. PubMed ID: 19229116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypertension and heart].
    Hennersdorf MG; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():27-30. PubMed ID: 16802514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension.
    Tomiyama M; Horio T; Kamide K; Nakamura S; Yoshihara F; Nakata H; Nakahama H; Kawano Y
    J Hum Hypertens; 2007 Mar; 21(3):212-9. PubMed ID: 17167525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left ventricular mass: impact on left ventricular contractile function and its reversibility in patients undergoing aortic valve replacement.
    Taniguchi K; Takahashi T; Toda K; Matsue H; Shudo Y; Shintani H; Mitsuno M; Sawa Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):588-95. PubMed ID: 17689973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy.
    Asmar R; Garcia-Puig J; Gosse P; Karpov YA; De Leeuws PW; Magometschniggs D; Matos L; Schmieder R
    Vasc Health Risk Manag; 2007; 3(4):371-80. PubMed ID: 17969366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis suggests regression of left ventricular hypertrophy during antihypertensive treatment is linked to reduced risk of cardiovascular disease.
    Evid Based Cardiovasc Med; 2004 Mar; 8(1):22-3; discussion 24-5. PubMed ID: 16379885
    [No Abstract]   [Full Text] [Related]  

  • 37. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.